Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — Q1 2020 Earnings Presentation
13 slides from Laboratorio Reig Jofre's earnings presentation, May 7, 2020
Slide 1: Results First Quarter 2020
35 RESULTS First Quarter 2020
Slide 2: Disclaimer
DISCLAIMER This presentation may contain forward-looking statements, including statements regarding Reig Jofre's intent, beliefs and expectations regarding business and operations, market conditions, operating results and financial position, capital adequacy, specific risk provisions and management
Slide 3: Table of Contents
TABLE of CONTENTS 01. 2020 FIRST QUARTER RESULTS 02. PERFORMANCE OF BUSINESS UNITS 03. INCOME STATEMENT AND BALANCE SHEET 04. O U T L O O K 2 0 2 0 PAGE 3
Slide 4: Sales 62M€ and EBITDA 8M€ in Q1 2020
REIG JOFRE invoices € 62M in the First Quarter of 2020, with a growth of 26% +26% Relevant growth in Pharmaceutical Technologies, + 12%, quantitative leap in Specialty SALES Pharmacare, + 92% and good performance in Consumer Healthcare + 7% 62M€ The growth reflects the revenue from the new Osteo
Slide 5: Revenue per Business Unit
Revenue per Business Unit PHARMACEUTICAL Growth of injectables linked to ICU treatment of intubated COVID-19 patients. Hospital sales TECHNOLOGIES focused on sedative, analgesic and muscle relaxant products manufactured in Barcelona. Antibiotics Injectables / lyophilized Increase in the sale of
Slide 6: Sales by Geographic Area
SPAIN Rest of EUROPE Rest of WORLD Sales by Geographic Area 47% 43% 10% 29.4M€ 26.4M€ 6.2M€ % International Sales* European Spain Union The Spanish market grew by 60% 47% 38% due to the effect of the new PHARMACEUTICAL Osteoarticular business and TECHNOLOGIES 57% manufacture for the essential medi
Slide 7: Income Statement and Balance Sheet Q1 2020
Q1 2020 INCOME STATEMENT BALANCE SHEET PAGE 7
Slide 8: Income Statement Q1 2020
Income Statement Q1 2020 thousands of euros 31/03/2020 31/03/2019 QoQ performance Net turnover 62,060 49,343 A growth in sales of 26% was achieved driven by revenue Procurements -23,726 -19,275 from the new Osteoarticular product business, which Changes invent. finished goods/work in progress -870
Slide 9: Balance Q1 2020: Assets and Investment
Balance Q1 2020 5.5 thousands of euros 31/03/2020 31/03/2019 ASSETS INVESTMENT Q1 Goodwill Other intangible assets 29,402 86,641 27,515 48,625 2020 million € Property, plant and equipment 84,240 57,736 Capitalization R+D Investments in associates/affiliates 1,223 311 Equity instruments fair value 12
Slide 10: Balance Q1 2020: Equity, Liabilities and Net Debt
Balance Q1 2020 thousands of euros 31/03/2020 31/03/2019 NET FINANCIAL DEBT Debt|EBITDA EQUITY AND LIABILITIES Capital 38,031 32,525 Q1 56 Q1 Share premium 19,000 0 2020 million € 2020 2.52 Treasury shares -1,137 -900 Reserves 123,470 119,092 53 closure 2.67 Other equity instruments 62 34 closure Pr
Slide 11: Outlook 2020
Outlook 2020 We expect a 2020 of growth in sales and profit, despite market uncertainties. In the second half of the year, revenues from Osteoarticular products will already reflect this business’s organic growth. The second quarter of the year will reflect the growth in the production of essential
Slide 12: Links and Supplementary Information
LINKS AND SUPPLEMENTARY INFORMATION LATEST NEWS www.reigjofre.com/es/noticias SUBSCRIPTION CENTRE http://www.reigjofre.com/es/noticias/centro-suscripcion PAGE 12
Slide 13: Thank you
Table of Thank you Av. de les Flors 08970 Sant Joan Despi, Barcelona, Spain T. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com